Research and Markets: Diabetic Foot Ulcers Therapeutics Pipeline Report H2 2014 - Analysis of 26 Companies & 37 Drug Profiles

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/g8sk47/diabetic_foot) has announced the addition of the "Diabetic Foot Ulcers - Pipeline Review, H2 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • Derma Sciences, Inc.
  • GlaxoSmithKline plc
  • CardioVascular BioTherapeutics, Inc.
  • Stratatech Corporation
  • Tissue Med Biosciences
  • Reliance Life Sciences Pvt. Ltd.
  • Celgene Corporation
  • Kaken Pharmaceutical Co., Ltd.
  • CytoTools AG
  • NovaLead Pharma Pvt. Ltd.
  • FirstString Research, Inc.
  • Lumosa Therapeutics Co., Ltd.
  • CoDa Therapeutics, Inc.
  • Adocia
  • Plurogen Therapeutics, Inc.
  • EyeGene, Inc.
  • Izun Pharmaceuticals Corporation
  • MacroCure
  • Royer Biomedical, Inc.
  • Oneness Biotech Co., Ltd.
  • Aprogen, Inc.
  • Pergamum AB
  • Dipexium Pharmaceuticals LLC
  • Kasiak Research Pvt. Ltd.
  • Innovaxis
  • Grupo Praxis Pharmaceutical SA

Drug Profiles

  • pexiganan acetate
  • DermaPro
  • trafermin
  • Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases
  • ON-101
  • DSC-127
  • CureXcell
  • Granexin
  • Vivefoot
  • ReliDerm-DT
  • CVBT-141B
  • CODA-001
  • PX-070101
  • IZN-6D4
  • CSTC-1
  • PluroGel N
  • esmolol hydrochloride
  • gentamicin sulfate
  • GSK-1278863
  • PDA-002
  • TMBP-3
  • coagulation factor XIVa (human)
  • AP-102
  • Cyndacel-M
  • EG-Decorin
  • STD-06
  • Nu-2
  • Nu-3
  • MT-003
  • Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers

For more information visit http://www.researchandmarkets.com/research/g8sk47/diabetic_foot

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals